Diagnosis of atypical fibroxanthoma--a case report.

Atypical fibroxanthoma has a wide spectrum of histological and cytological appearances. One recently described variant is atypical fibroxanthoma with touton type giant cells. We also came across this case in a 24 year old male student who presented with a sub epidermal nodule on the right shoulder for the last one year. The lesion was aspirated, it should spindle shaped cells, giant cells, and collagen. Giant cells had multiple vacuoles and pink colored granules in their cytoplasm. He was diagnosed as atypical fibroxanthoma. The tumor was excised and histopathology confirmed the diagnosis. Complete excision was curative.

A study of the effect of tamoxifen on serum lipoprotein profiles in premenopausal and postmenopausal women with breast carcinoma and associated risk of cardiovascular disease.

To examine the effect of tamoxifen on serum lipoprotein profiles of premenopausal and postmenopausal patients of breast carcinoma (without and with cardiovascular disease) we performed a short term evaluation of serum lipoprotein profiles of 38 pre and 42 post menopausal subjects of breast carcinoma (without and with cardiovascular disease) at baseline and after 3 and 6 months of tamoxifen therapy. The serum lipoprotein profiles of premenopausal patients of breast carcinoma, both without and with cardiovascular disease, showed no significant variation, after 3 and 6 months of tamoxifen treatment than the corresponding baseline values of premenopausal subjects. However, in postmenopausal subjects of breast carcinoma (both without and with cardiovascular disease), serum TC, Apo-B, and Lp (a) were significantly decreased and serum TG, HDL and Apo A1 were significantly elevated, after 3 and 6 months of tamoxifen treatment, than the corresponding baseline values of postmenopausal subjects. Also, the comparison of the results of the present study for pre and postmenopausal patients of breast cancer revealed that the administration of tamoxifen, as an adjuvant therapy for breast cancer, is estrogenic and beneficial for postmenopausal patients of breast carcinoma (both without and with the risk of cardiovascular disease) as the drug minimises the risk of cardivascular disease by bringing significant improvement in serum lipoprotein profiles of the patients. But the drug fails to bring any significant beneficial effect on serum lipoproteins of hyperiipoproteinemic patients of breast cancer.

A comparative of the effect of tamoxifen on serum lipid and lipoprotein profile in premenopausal & postmenopausal women with breast carcinoma & associated risk of vascular complication.

To examine the effect of tamoxifen on serum lipid and lipoprotein profile of premenopausal and postmenopausal patients of breast carcinoma (with and without vascular disease) we performed a short term evaluation of serum lipid and lipoprotein profile of 38 pre and 42 post menopausal subjects of breast carcinoma (with and without vascular disease) at baseline and during 3 and 6 months of tamoxifen therapy. The lipid & Lp profile of premenopausal patients of Breast carcinoma without vascular disease showed no significant variation after 3 and 6 months of tamoxifen treatment than the corresponding baseline values, but in premenopausal subjects of breast cancer with vascular disease and post menopausal subjects of breast carcinoma (both with and without vascular disease), Serum TC, Apo-B and Lp (a) were significantly decreased and serum HDL and Apo A-I were elevated significantly, However serum TG remain unaltered in premenopausal patients of breast carcinoma with vascular disease but found to be elevated significantly in postmenopausal subjects of breast cancer, both, with and without vascular disease, after 3 and 6 months of tamoxifen treatment, than the corresponding baseline values. Also, the comparison of the results of the present study for pre and postmenopausal patients of breast cancer revealed that the administration of tamoxifen, as adjuvant therapy for breast cancer, is beneficial for postmenopausal patients of breast carcinoma with vascular disease as the drug minimises the risk of vascular disease by bringing significant improvement in serum lipid and Lp profiles of the patients but does not have any significant beneficial effect on familial hyperlipidemic patients of breast cancer.